董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ulf Wiinberg | 男 | Director | 65 | 33.23万美元 | 未持股 | 2023-04-28 |
| Allison M. Jeynes Ellis | 女 | Director | 57 | 22.00万美元 | 未持股 | 2023-04-28 |
| Susan Hirsch | 女 | Director | 70 | 22.00万美元 | 未持股 | 2023-04-28 |
| Garo H. Armen | 男 | Chairman and Chief Executive Officer | 71 | 562.63万美元 | 未持股 | 2023-04-28 |
| Brian Corvese | 男 | Director | 66 | 58.95万美元 | 未持股 | 2023-04-28 |
| Timothy R. Wright | 男 | Lead Director | 66 | 36.75万美元 | 未持股 | 2023-04-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven O'Day | 男 | Chief Medical Officer | 61 | 131.12万美元 | 未持股 | 2023-04-28 |
| Garo H. Armen | 男 | Chairman and Chief Executive Officer | 71 | 562.63万美元 | 未持股 | 2023-04-28 |
| Christine M. Klaskin | 女 | Vice President of Finance | 57 | 62.81万美元 | 未持股 | 2023-04-28 |
董事简历
中英对照 | 中文 | 英文- Ulf Wiinberg
-
Ulf Wiinberg目前担任临床前疫苗研究公司X-VAX Technology，Inc.的首席执行官。在加入X-Vax之前，Wiinberg先生于2008年6月至2014年12月担任H.Lundbeck A/S（“；Lundbeck”；）的首席执行官。Lundbeck公司是一家全球制药公司，开发和营销治疗精神和神经疾病的药物。他此前曾任职于多个医疗保健行业协会的董事会，并担任Wyeth公司（世界上最大的研究驱动型制药公司之一，于2009年被Pfizer公司收购）的多种执行职务。他曾担任惠氏欧洲、非洲和中东地区总裁；消费者梦百合总裁；惠氏英国公司董事总经理，并担任多个商业职位。Wiinberg先生目前任职于总部位于比利时的全球生物制药公司UCB SA，瑞典生物制药公司Hansa Medical AB（主席）和瑞典工业公司Alfa Laval AB的董事会。
Ulf Wiinberg,has almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of X+Vax Technology A.S., a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Mr. Wiinberg previously served as Chief Executive Officer of H. Lundbeck A/S ("Lundbeck") from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several health care industry associations and held multiple executive roles at Wyeth, one of the world's largest research- driven pharmaceutical companies, when was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, Alfa Laval AB, a Swedish industrial company, and Agenus. - Ulf Wiinberg目前担任临床前疫苗研究公司X-VAX Technology，Inc.的首席执行官。在加入X-Vax之前，Wiinberg先生于2008年6月至2014年12月担任H.Lundbeck A/S（“；Lundbeck”；）的首席执行官。Lundbeck公司是一家全球制药公司，开发和营销治疗精神和神经疾病的药物。他此前曾任职于多个医疗保健行业协会的董事会，并担任Wyeth公司（世界上最大的研究驱动型制药公司之一，于2009年被Pfizer公司收购）的多种执行职务。他曾担任惠氏欧洲、非洲和中东地区总裁；消费者梦百合总裁；惠氏英国公司董事总经理，并担任多个商业职位。Wiinberg先生目前任职于总部位于比利时的全球生物制药公司UCB SA，瑞典生物制药公司Hansa Medical AB（主席）和瑞典工业公司Alfa Laval AB的董事会。
- Ulf Wiinberg,has almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of X+Vax Technology A.S., a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Mr. Wiinberg previously served as Chief Executive Officer of H. Lundbeck A/S ("Lundbeck") from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several health care industry associations and held multiple executive roles at Wyeth, one of the world's largest research- driven pharmaceutical companies, when was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, Alfa Laval AB, a Swedish industrial company, and Agenus.
- Allison M. Jeynes Ellis
-
Allison M.Jeynes Ellis，现为伦敦药物开发公司Avillion LLP“；Avillion”；的首席执行官、董事。在担任现任首席执行官之前，Jeynes-Ellis博士于2012年12月至2014年1月担任Avillion’；的首席医疗官。任职Avillion公司之前，Jeynes-Ellis博士曾在惠氏（Wyeth）、百时美施贵宝（Bristol-Myers Squibb）和诺华（Novartis）担任高级职务。她之前的附属机构还包括Cambridge Antibody Technology和Genentech、政府机构和医疗慈善机构。她曾管理专注于全球临床开发项目的团队，这些项目已导致欧洲和美国的药物批准，涉及一系列治疗领域。Jeynes-Ellis博士目前担任Blackstone Life Sciences的高级顾问。
Allison M. Jeynes Ellis,is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. Dr. Jeynes-Ellis has been the Chief Executive Officer of Avillion LLP ("Avillion"), a London-based drug development company since 2014. Prior to her current position as CEO, Dr. Jeynes-Ellis served as Avillion's Chief Medical Officer from December 2012 to January 2014. Before her tenure at Avillion, Dr. Jeynes-Ellis worked in senior roles at Wyeth, Bristol-Myers Squibb, and Novartis. Her previous affiliations also include Cambridge Antibody Technology and Genentech, government bodies and medical charities. She has managed teams focusing on global clinical development projects that have led to drug approvals in Europe and the United States, across a range of therapeutic areas. Dr. Jeynes-Ellis became the Chair of the Board of OxSonics Therapeutics ("OxSonics") in April 2021. OxSonics is a biotechnology company developing ultrasound-based drug delivery systems for the treatment of cancer. Dr. Jeynes-Ellis also sits on the Board of Directors of Anaveon and is a Senior Advisor to Blackstone Life Sciences and a Special Advisor to Abingworth. - Allison M.Jeynes Ellis，现为伦敦药物开发公司Avillion LLP“；Avillion”；的首席执行官、董事。在担任现任首席执行官之前，Jeynes-Ellis博士于2012年12月至2014年1月担任Avillion’；的首席医疗官。任职Avillion公司之前，Jeynes-Ellis博士曾在惠氏（Wyeth）、百时美施贵宝（Bristol-Myers Squibb）和诺华（Novartis）担任高级职务。她之前的附属机构还包括Cambridge Antibody Technology和Genentech、政府机构和医疗慈善机构。她曾管理专注于全球临床开发项目的团队，这些项目已导致欧洲和美国的药物批准，涉及一系列治疗领域。Jeynes-Ellis博士目前担任Blackstone Life Sciences的高级顾问。
- Allison M. Jeynes Ellis,is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. Dr. Jeynes-Ellis has been the Chief Executive Officer of Avillion LLP ("Avillion"), a London-based drug development company since 2014. Prior to her current position as CEO, Dr. Jeynes-Ellis served as Avillion's Chief Medical Officer from December 2012 to January 2014. Before her tenure at Avillion, Dr. Jeynes-Ellis worked in senior roles at Wyeth, Bristol-Myers Squibb, and Novartis. Her previous affiliations also include Cambridge Antibody Technology and Genentech, government bodies and medical charities. She has managed teams focusing on global clinical development projects that have led to drug approvals in Europe and the United States, across a range of therapeutic areas. Dr. Jeynes-Ellis became the Chair of the Board of OxSonics Therapeutics ("OxSonics") in April 2021. OxSonics is a biotechnology company developing ultrasound-based drug delivery systems for the treatment of cancer. Dr. Jeynes-Ellis also sits on the Board of Directors of Anaveon and is a Senior Advisor to Blackstone Life Sciences and a Special Advisor to Abingworth.
- Susan Hirsch
-
Susan Hirsch，在投资管理和金融领域拥有超过40年的经验。Unit 2021年2月，她在TIAA公司Nuveen担任董事总经理和投资组合经理，负责管理超过200亿美元的资产，包括拥有66亿美元资产的TIAA-CREF大盘成长基金。在2005年加入Nuveen之前，她曾以Jennison Associates的身份担任中型增长和技术部门投资组合的执行副总裁兼投资组合经理。赫什女士之前的经历还包括在雷曼兄弟全球资产管理公司和德尔福资产管理公司担任精选成长股投资组合高级投资组合经理的投资管理职位。她的职业生涯始于美邦和雷曼兄弟的分析师，在那里，她的量化模型的成功使她随后在1991年、1992年和1993年被公认为小盘成长股的顶级机构分析师。Hirsch女士拥有布鲁克林学院的会计学学士学位。
Susan Hirsch,has over 40 years of experience in investment management and finance. Until February 2021, she was a Managing Director and Portfolio Manager at Nuveen, a TIAA company, where she was responsible for managing over $20 billion in assets including the TIAA-CREF Large-Cap Growth Fund with $6.6 billion in assets. Prior to joining Nuveen in 2005, she served as Executive Vice President and Portfolio Manager for the Mid-Cap Growth and Technology Sector portfolios as Jennison Associates. Ms. Hirsch's previous experience also includes investment management positions at Lehman Brothers Global Asset Management and Delphi Asset Management as a Senior Portfolio Manager for the Selected Growth Stock Portfolio. She began her career as an analyst at Smith Barney and Lehman Brothers where the success of her quantitative model led to her subsequent recognition as a top ranked Institutional analyst for small cap growth stocks in 1991, 1992 and 1993. Ms. Hirsch holds a BS in Accounting from Brooklyn College. - Susan Hirsch，在投资管理和金融领域拥有超过40年的经验。Unit 2021年2月，她在TIAA公司Nuveen担任董事总经理和投资组合经理，负责管理超过200亿美元的资产，包括拥有66亿美元资产的TIAA-CREF大盘成长基金。在2005年加入Nuveen之前，她曾以Jennison Associates的身份担任中型增长和技术部门投资组合的执行副总裁兼投资组合经理。赫什女士之前的经历还包括在雷曼兄弟全球资产管理公司和德尔福资产管理公司担任精选成长股投资组合高级投资组合经理的投资管理职位。她的职业生涯始于美邦和雷曼兄弟的分析师，在那里，她的量化模型的成功使她随后在1991年、1992年和1993年被公认为小盘成长股的顶级机构分析师。Hirsch女士拥有布鲁克林学院的会计学学士学位。
- Susan Hirsch,has over 40 years of experience in investment management and finance. Until February 2021, she was a Managing Director and Portfolio Manager at Nuveen, a TIAA company, where she was responsible for managing over $20 billion in assets including the TIAA-CREF Large-Cap Growth Fund with $6.6 billion in assets. Prior to joining Nuveen in 2005, she served as Executive Vice President and Portfolio Manager for the Mid-Cap Growth and Technology Sector portfolios as Jennison Associates. Ms. Hirsch's previous experience also includes investment management positions at Lehman Brothers Global Asset Management and Delphi Asset Management as a Senior Portfolio Manager for the Selected Growth Stock Portfolio. She began her career as an analyst at Smith Barney and Lehman Brothers where the success of her quantitative model led to her subsequent recognition as a top ranked Institutional analyst for small cap growth stocks in 1991, 1992 and 1993. Ms. Hirsch holds a BS in Accounting from Brooklyn College.
- Garo H. Armen
-
Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
Garo H. Armen, Executive Chairman, is one of founders and joined in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agen Inc., a biotechnology company he co founded in 1994. From mid 2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agen Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology biness in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and stainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY. - Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
- Garo H. Armen, Executive Chairman, is one of founders and joined in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agen Inc., a biotechnology company he co founded in 1994. From mid 2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agen Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology biness in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and stainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY.
- Brian Corvese
-
Brian Corvese，自1999年以来，他一直担任Vencor Capital（一家在中东和地中海地区进行电信和技术投资的私募股权公司）的总裁和创始人。在Vencor工作之前，他曾担任索罗斯基金管理公司（当时世界上最大的对冲基金）的董事总经理和合伙人，从事美国和全球股票市场的投资。从1988年到1996年，他是Chancellor Capital Management（一家250亿美元的资金管理公司）的合伙人。在Chancellor任职期间，他曾担任投资组合经理，负责基础行业、重组、特殊情况、公司治理投资的投资，以及创立和管理自己的对冲基金。从1981年到1988年，Corvese先生在Drexel Burnham Lambert（“Drexel”）担任股票分析师，跟踪化学和特种化学行业，并参与了大量的并购活动。在Drexel任职期间，他是机构投资者（Institutional Investor）排名的顶级化学和特种化学研究团队的成员。他目前担任MiNK Therapeutics， Inc.（位于埃及开罗的国家电信公司）和Protagenic Therapeutics （Agenus的子公司，位于加拿大安大略省）的董事会成员。他获得Rhode Island大学的金融和政治学学位，并就读于纽约大学研究生院。
Brian Corvese,has been the President and Founder of Vencor Capital ("Vencor"), a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management ("Chancellor"), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert ("Drexel") as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. In addition to serving on the Board of MiNK, Mr. Corvese currently serves on the Board of Directors of Agenus , the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School. - Brian Corvese，自1999年以来，他一直担任Vencor Capital（一家在中东和地中海地区进行电信和技术投资的私募股权公司）的总裁和创始人。在Vencor工作之前，他曾担任索罗斯基金管理公司（当时世界上最大的对冲基金）的董事总经理和合伙人，从事美国和全球股票市场的投资。从1988年到1996年，他是Chancellor Capital Management（一家250亿美元的资金管理公司）的合伙人。在Chancellor任职期间，他曾担任投资组合经理，负责基础行业、重组、特殊情况、公司治理投资的投资，以及创立和管理自己的对冲基金。从1981年到1988年，Corvese先生在Drexel Burnham Lambert（“Drexel”）担任股票分析师，跟踪化学和特种化学行业，并参与了大量的并购活动。在Drexel任职期间，他是机构投资者（Institutional Investor）排名的顶级化学和特种化学研究团队的成员。他目前担任MiNK Therapeutics， Inc.（位于埃及开罗的国家电信公司）和Protagenic Therapeutics （Agenus的子公司，位于加拿大安大略省）的董事会成员。他获得Rhode Island大学的金融和政治学学位，并就读于纽约大学研究生院。
- Brian Corvese,has been the President and Founder of Vencor Capital ("Vencor"), a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management ("Chancellor"), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert ("Drexel") as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. In addition to serving on the Board of MiNK, Mr. Corvese currently serves on the Board of Directors of Agenus , the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School.
- Timothy R. Wright
-
Timothy R. Wright，他自2019年4月以来一直担任Isosceles的执行主席。他还担任BIORG， INC 。的总裁兼首席执行官（2013年11月以来）。在担任这些职位之前，他是MiMedX（再生医学公司）的首席执行官。他目前还担任Agenus Inc.的董事会成员（2006年以来）。此外，他是the Ohio State University Comprehensive Cancer Center Drug Development Institute的创始人和前任主席。他还担任Washington University Medical School和North Carolina Veterinary School的顾问委员会成员。Wright先生曾在Covidien（现为Medtronic）、Teva Pharmaceuticals Industries Ltd.、DuPont Merck、Elan Bio-Pharmaceuticals、M2Gen Corp.担任多个行政职务。
Timothy R. Wright is the Chief Executive Officer of MiMedX Group, Inc., a position that he has held since May 2019. MiMedX is an advanced wound care and emerging therapeutic biologics company. Mr. Wright also currently serves on the board of directors of Agen Inc., which he has served on since 2006. Mr. Wright also serves as a Partner at Signal Hill Advisors, LLC, a position he has held since February 2011. In addition, Mr. Wright serves as Chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute and Director of the Ohio State University Innovation Foundation. Mr. Wright previoly held several executive roles at Covidien (now Medtronic), Teva Pharmaceuticals Indtries Ltd., DuPont Merck, Elan Bio Pharmaceuticals, M2Gen Corp. and Curaxis Pharmaceuticals Corporation. - Timothy R. Wright，他自2019年4月以来一直担任Isosceles的执行主席。他还担任BIORG， INC 。的总裁兼首席执行官（2013年11月以来）。在担任这些职位之前，他是MiMedX（再生医学公司）的首席执行官。他目前还担任Agenus Inc.的董事会成员（2006年以来）。此外，他是the Ohio State University Comprehensive Cancer Center Drug Development Institute的创始人和前任主席。他还担任Washington University Medical School和North Carolina Veterinary School的顾问委员会成员。Wright先生曾在Covidien（现为Medtronic）、Teva Pharmaceuticals Industries Ltd.、DuPont Merck、Elan Bio-Pharmaceuticals、M2Gen Corp.担任多个行政职务。
- Timothy R. Wright is the Chief Executive Officer of MiMedX Group, Inc., a position that he has held since May 2019. MiMedX is an advanced wound care and emerging therapeutic biologics company. Mr. Wright also currently serves on the board of directors of Agen Inc., which he has served on since 2006. Mr. Wright also serves as a Partner at Signal Hill Advisors, LLC, a position he has held since February 2011. In addition, Mr. Wright serves as Chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute and Director of the Ohio State University Innovation Foundation. Mr. Wright previoly held several executive roles at Covidien (now Medtronic), Teva Pharmaceuticals Indtries Ltd., DuPont Merck, Elan Bio Pharmaceuticals, M2Gen Corp. and Curaxis Pharmaceuticals Corporation.
高管简历
中英对照 | 中文 | 英文- Steven O'Day
Steven O'Day，自2021年1月起担任Agenus Inc.首席医疗官。Dr. O'Day是CTLA-4抑制的先驱，在200多项临床试验中担任主要研究者。2015年至加入Agenus，担任普罗维登斯圣约翰健康中心John Wayne癌症研究所免疫-Onoclogy主任和临床研究主任。O'Day博士于1988年获得约翰霍普金斯医学院的医学博士学位，并于1983年获得威廉姆斯学院的化学学士学位。此外，O'Day博士还在达纳 Farber/哈佛癌症中心完成了他的医学肿瘤学研究金。
Steven O'Day,has been Agenus Inc. Chief Medical Officer since January 2021. Dr. O'Day is a pioneer in CTLA-4 inhibition, and has been the principal investigator in more than 200 clinical trials. From 2015 until joining Agenus, was Director of Immuno-Oncology and Director of Clinical Research at John Wayne Cancer Institute at Providence Saint John's Health Center. Dr. O'Day received his medical degree in 1988 from Johns Hopkins School of Medicine and his BA in Chemistry from Williams College in 1983. Additionally, Dr. O'Day did his medical oncology fellowship at the Dana Farber/Harvard Cancer Center.- Steven O'Day，自2021年1月起担任Agenus Inc.首席医疗官。Dr. O'Day是CTLA-4抑制的先驱，在200多项临床试验中担任主要研究者。2015年至加入Agenus，担任普罗维登斯圣约翰健康中心John Wayne癌症研究所免疫-Onoclogy主任和临床研究主任。O'Day博士于1988年获得约翰霍普金斯医学院的医学博士学位，并于1983年获得威廉姆斯学院的化学学士学位。此外，O'Day博士还在达纳 Farber/哈佛癌症中心完成了他的医学肿瘤学研究金。
- Steven O'Day,has been Agenus Inc. Chief Medical Officer since January 2021. Dr. O'Day is a pioneer in CTLA-4 inhibition, and has been the principal investigator in more than 200 clinical trials. From 2015 until joining Agenus, was Director of Immuno-Oncology and Director of Clinical Research at John Wayne Cancer Institute at Providence Saint John's Health Center. Dr. O'Day received his medical degree in 1988 from Johns Hopkins School of Medicine and his BA in Chemistry from Williams College in 1983. Additionally, Dr. O'Day did his medical oncology fellowship at the Dana Farber/Harvard Cancer Center.
- Garo H. Armen
Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
Garo H. Armen, Executive Chairman, is one of founders and joined in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agen Inc., a biotechnology company he co founded in 1994. From mid 2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agen Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology biness in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and stainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY.- Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
- Garo H. Armen, Executive Chairman, is one of founders and joined in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agen Inc., a biotechnology company he co founded in 1994. From mid 2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agen Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology biness in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and stainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY.
- Christine M. Klaskin
Christine M. Klaskin，自2012年起担任董事会的成员。自2006年以来，她是Agenus公司（纳斯达克交易代码：AGEN）的财务副总裁，一家开发和商业化技术来治疗癌症和传染性疾病的生物技术公司。克拉斯女士在1996年加入Agenus公司，并担任各种财务职位。从1987年到1996年，她任职于安达信会计师事务所，最近担任审计经理。克拉斯女士获得乔治华盛顿大学的会计学学士学位。
Christine M. Klaskin,has served as Treasurer since July 2017. Since October 2006, Ms. Klaskin has also served as Vice President, Finance of Agenus. Since joining Agenus in 1996 as finance manager, Ms. Klaskin has held various positions within Agenus' finance department. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.- Christine M. Klaskin，自2012年起担任董事会的成员。自2006年以来，她是Agenus公司（纳斯达克交易代码：AGEN）的财务副总裁，一家开发和商业化技术来治疗癌症和传染性疾病的生物技术公司。克拉斯女士在1996年加入Agenus公司，并担任各种财务职位。从1987年到1996年，她任职于安达信会计师事务所，最近担任审计经理。克拉斯女士获得乔治华盛顿大学的会计学学士学位。
- Christine M. Klaskin,has served as Treasurer since July 2017. Since October 2006, Ms. Klaskin has also served as Vice President, Finance of Agenus. Since joining Agenus in 1996 as finance manager, Ms. Klaskin has held various positions within Agenus' finance department. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.